Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has sold a 9.9% stake in the diagnostics company, generating Rs 986 crore. This significant divestment occurred through multiple bulk and block deals on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Thursday.

Details of the Transaction

The sale involved 1,57,69,696 equity shares and was executed with a price range between Rs 624 and Rs 631.71 per share. The transaction was split into block deals, which accounted for more than 1.31 crore shares, and bulk deals that included 10 lakh shares on the NSE and 16.01 lakh shares on the BSE.

Following this transaction, Docon Technologies' stake in Thyrocare Technologies decreased from 60.92% to 51.02%. This marks another significant sale by Docon, following a similar transaction last October when it sold a 10% stake for Rs 667 crore.

Key Buyers and Market Reaction

The stake sale attracted numerous institutional investors and insurance companies. Notable buyers included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance firms such as Kotak Mahindra Life Insurance and Tata AIA Life Insurance participated, alongside global entities like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.

In the aftermath of the transaction, Thyrocare Technologies' stock experienced a rise, gaining nearly 3% to reach Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE.

Market Context and Future Implications

This move by Docon Technologies comes amid a dynamic period for Thyrocare Technologies, as the company continues to navigate a competitive diagnostics market. The participation of high-profile investors underscores the confidence in Thyrocare's business model and growth prospects.

While the specifics of other buyers in the bulk deals remain undisclosed, the overall response from the market has been positive, reflecting investor optimism about Thyrocare's future performance.